Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model

Transplantation

Volumn 62, Issue 3, 1996, Pages 311-316

  Andoh, Takeshi F ^a,b   Lindsley, Jessie ^b   Franceschini, Nora ^b   Bennett, William M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029821746     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199608150-00002     Document Type: Article

References (25)

1. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 1654.
2. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
3. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus - a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209.
4. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide [Review]. Med Res Rev 1994; 14: 1.
5. Tu Y, Stepkowski SM, Chou TC, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 59: 177.
6. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922.
7. Ryffel B, Weber E, Mihatsch MJ. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. Exp Nephrol 1994; 2: 324.
8. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507.
9. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation 1994; 57: 483.
10. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491.
11. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats. Transplantation 1995; 60: 89.
12. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Functional and structural characteristics of experimental FK506 nephrotoxicity. Clin Exp Pharmacol Physiol 1995; 22: 646.
13. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 1990; 49: 445.
14. Whiting PH, Woo J, Adam BJ, Hasan NU, Davidson RJ, Thomson AW. Toxicity of rapamycin - a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 1991; 52: 203.
15. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526.
16. Thliveris JA, Yatscoff RW. Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit. Transplantation 1995; 59: 427.
17. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139.
18. Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen HK. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995; 37: F13.
19. Cosio FG. Effects of high glucose concentrations on human mesangial cell proliferation. J Am Soc Nephrol 1995; 5: 1600.
20. Shehata M, Cope GH, Johnson TS, Raftery AT, Elnahas AM. Cyclosporine enhances the expression of TGF-beta in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 1487.
21. Cosio FG, Wilmer WA. Effects of high glucose concentration on c-fos - role of protein kinase C. Kidney Int 1995; 48: S12.
22. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 89: 2873.
23. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992; 41: 107.
24. Ayo SH, Radnik R, Garoni JA, Troyer DA, Kreisberg JI. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571.
25. Ptachcinski RJ, Carpenter BJ, Burckart GJ. Effect of erythromycin on cyclosporine levels. N Engl J Med 1985; 313: 1416.